Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425154 | 1.00 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30514301 | 0.85 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL42133 | 0.84 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6002015 | 0.84 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL12658269 | 0.84 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL1532519 | 0.83 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL8941498 | 0.83 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL98410 | 0.83 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL154357 | 0.83 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL7618888 | 0.83 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365632-A1 | A GROUP OF PEPTIDE DERIVATIVE OMICSYNINS WITH ANTIVIRAL ACTIVITY AND USES THEREOF | INSTITUTE OF MEDICINAL BIOTECHNOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-4123031-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | The Regents of The University of California (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3283638-B1 | METHODS FOR DETECTING AGGLUTINATION AND USE OF KITS IN PRACTICING THE SAME | UNIV CALIFORNIA (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210403978-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-30 | — | — | US | disclosed |
| US-11149296-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200232005-A1 | Methods of Producing and Using Single-Stranded Deoxyribonucleic Acids and Compositions for Use in Practicing the Same | TAKARA BIO USA, INC. | 2020-07-23 | — | — | US | disclosed |
| US-10584363-B2 | Methods of producing and using single-stranded deoxyribonucleic acids and compositions for use in practicing the same | TAKARA BIO USA, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20180100181-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-12 | — | — | US | disclosed |
| US-20170349927-A1 | METHODS OF PRODUCING AND USING SINGLE-STRANDED DEOXYRIBONUCLEIC ACIDS AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | TAKARA BIO USA, INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365632-A1 | A GROUP OF PEPTIDE DERIVATIVE OMICSYNINS WITH ANTIVIRAL ACTIVITY AND USES THEREOF | CCL5, CYTH3, HRH3 | SLC28A1 4423/4885SLC28A2 4462/4885SLC29A1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.